Oncolytics Biotech Analyst Ratings
Oncolytics Biotech Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/13/2023 | 267.67% | HC Wainwright & Co. | $15 → $5 | Maintains | Buy |
| 08/16/2023 | 1003.02% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy |
| 06/29/2023 | 1003.02% | HC Wainwright & Co. | $15 → $15 | Reiterates | Buy → Buy |
| 06/23/2023 | 267.67% | Canaccord Genuity | → $5 | Reiterates | Buy → Buy |
| 06/07/2023 | 1003.02% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy |
| 05/26/2023 | 1003.02% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy |
| 05/24/2023 | 561.81% | JonesTrading | → $9 | Initiates Coverage On | → Buy |
| 03/14/2023 | 1003.02% | HC Wainwright & Co. | → $15 | Reiterates | → Buy |
| 03/06/2023 | 267.67% | Canaccord Genuity | $6 → $5 | Maintains | Buy |
| 10/06/2022 | 120.6% | Maxim Group | → $3 | Initiates Coverage On | → Buy |
| 02/17/2021 | 1003.02% | HC Wainwright & Co. | → $15 | Initiates Coverage On | → Buy |
| 05/11/2020 | 341.21% | RBC Capital | $9 → $6 | Maintains | Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/13/2023 | 267.67% | HC Wainwright & Co. | 15 美元 → 5 美元 | 维护 | 买 |
| 08/16/2023 | 1003.02% | HC Wainwright & Co. | → 15 美元 | 重申 | 购买 → 购买 |
| 06/29/2023 | 1003.02% | HC Wainwright & Co. | 15 美元 → 15 美元 | 重申 | 购买 → 购买 |
| 06/23/2023 | 267.67% | Canaccord Genu | → 5 美元 | 重申 | 购买 → 购买 |
| 06/07/2023 | 1003.02% | HC Wainwright & Co. | → 15 美元 | 重申 | 购买 → 购买 |
| 05/26/2023 | 1003.02% | HC Wainwright & Co. | → 15 美元 | 重申 | 购买 → 购买 |
| 05/24/2023 | 561.81% | JonesTrading | → 9 美元 | 启动覆盖范围开启 | → 购买 |
| 03/14/2023 | 1003.02% | HC Wainwright & Co. | → 15 美元 | 重申 | → 购买 |
| 03/06/2023 | 267.67% | Canaccord Genu | 6 美元 → 5 美元 | 维护 | 买 |
| 2022 年 6 月 10 日 | 120.6% | Maxim 集团 | → 3 美元 | 启动覆盖范围开启 | → 购买 |
| 02/17/2021 | 1003.02% | HC Wainwright & Co. | → 15 美元 | 启动覆盖范围开启 | → 购买 |
| 05/11/2020 | 341.21% | 加拿大皇家银行资本 | 9 美元 → 6 美元 | 维护 | 跑赢大盘 |
What is the target price for Oncolytics Biotech (ONCY)?
Oncolytics Biotech（ONCY）的目标价格是多少？
The latest price target for Oncolytics Biotech (NASDAQ: ONCY) was reported by HC Wainwright & Co. on November 13, 2023. The analyst firm set a price target for $5.00 expecting ONCY to rise to within 12 months (a possible 267.67% upside). 9 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2023年11月13日公布了Oncolytics Biotech（纳斯达克股票代码：ONCY）的最新目标股价。该分析公司将目标股价定为5.00美元，预计ONCY将在12个月内升至12个月内（可能上涨267.67％）。去年有9家分析公司公布了评级。
What is the most recent analyst rating for Oncolytics Biotech (ONCY)?
Oncolytics Biotech（ONCY）的最新分析师评级是多少？
The latest analyst rating for Oncolytics Biotech (NASDAQ: ONCY) was provided by HC Wainwright & Co., and Oncolytics Biotech maintained their buy rating.
HC Wainwright & Co. 提供了Oncolytics Biotech（纳斯达克股票代码：ONCY）的最新分析师评级，Oncolytics Biotech维持买入评级。
When is the next analyst rating going to be posted or updated for Oncolytics Biotech (ONCY)?
Oncolytics Biotech（ONCY）的下一份分析师评级何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Oncolytics Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Oncolytics Biotech was filed on November 13, 2023 so you should expect the next rating to be made available sometime around November 13, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Oncolytics Biotech的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Oncolytics Biotech的最新评级是在2023年11月13日发布的，因此您应该预计下一个评级将在2024年11月13日左右公布。
Is the Analyst Rating Oncolytics Biotech (ONCY) correct?
分析师对Oncolytics Biotech（ONCY）的评级是否正确？
While ratings are subjective and will change, the latest Oncolytics Biotech (ONCY) rating was a maintained with a price target of $15.00 to $5.00. The current price Oncolytics Biotech (ONCY) is trading at is $1.36, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Oncolytics Biotech（ONCY）评级维持不变，目标股价为15.00美元至5.00美元。Oncolytics Biotech（ONCY）目前的交易价格为1.36美元，超出了分析师的预期区间。